Tonix Pharmaceuticals Holding Corp.
TNXPNasdaq
$12.43
↑ +4.9%Jul 17 close · end-of-day
Price
1Y↓ -72.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$170.4M
Enterprise Value
-$15.1M
P/E
—
P/S
9.7
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
-76.7%
Dividend Yield
—
Revenue (TTM)
$17.6M
Net Income (TTM)
-$147.4M
Free Cash Flow (TTM)
-$130.6M
Gross Margin
—
Operating Margin
-861.2%
Net Margin
-839.5%
ROE
-64.9%
ROIC
-286.6%
Debt / Equity
—
Net Cash
$185.5M
Return 1Y
-73.7%
Company profile
Tonix Pharmaceuticals Holding Corp. focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
- CEO
- Seth Lederman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- New Jersey
- Website
- tonixpharma.com
Earnings
TNXP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.9M↑ +183.2%
Diluted EPS-$2.93↑ +3.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $7.8M | $10.1M | $13.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$50.5M | -$92.3M | -$112.1M | -$118.4M | -$136.7M | -$125.7M |
| Net income | -$50.5M | -$92.3M | -$110.2M | -$116.7M | -$130.0M | -$124.0M |
| Diluted EPS | — | -$8.10 | -$20.01 | -$14,720.25 | -$176.60 | -$14.57 |
| Operating cash flow | -$48.6M | -$75.6M | -$98.1M | -$102.0M | -$60.9M | -$99.8M |
| Free cash flow | -$57.1M | -$110.9M | -$146.2M | -$109.9M | -$61.0M | -$103.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -1523.9% | -1354.3% | -959.1% |
| Net margin | — | — | — | -1501.8% | -1288.3% | -946.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.8M | $2.6M | $2.4M | $2.0M | $3.3M | $5.4M | $6.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$77.3M | -$15.6M | -$22.5M | -$16.1M | -$28.3M | -$33.1M | -$48.3M | -$41.5M |
| Net income | -$78.8M | -$14.2M | -$22.1M | -$16.8M | -$28.3M | -$32.0M | -$46.9M | -$40.2M |
| Diluted EPS | -$1,920.85 | -$22.68 | $2,302.65 | -$2.84 | -$3.86 | -$3.59 | -$4.28 | -$2.93 |
| Operating cash flow | -$9.9M | -$18.8M | -$14.6M | -$16.6M | -$14.8M | -$28.8M | -$39.6M | -$42.3M |
| Free cash flow | -$9.9M | -$18.8M | -$14.6M | -$16.6M | -$15.4M | -$29.7M | -$41.5M | -$44.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -3501.6% | -551.2% | -870.6% | -660.9% | -1416.2% | -1005.1% | -895.8% | -603.9% |
| Net margin | -3567.8% | -503.6% | -856.2% | -692.8% | -1415.0% | -972.9% | -870.3% | -584.4% |
Company news
Jul 13, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.